HDAC inhibitors in cancer therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Reversible lysine acetylation is a major posttranslational modification in histones and nonhistone proteins. Modulation of this process is an important target for drug discovery, most successfully through the inhibition of zinc-dependent histone deacetylases (HDACs). There are five HDAC inhibitors approved for the treatment of hematological cancers and more than 20 others in clinical development. This chapter reviews the current state of the art of HDAC therapy in terms of the biological functions of the enzymes, the structural classes of HDAC inhibitors, and their utility in cancer therapy based on the data from recent clinical trials.
Original languageEnglish
Title of host publicationHistone Modifications in Therapy
PublisherElsevier
Chapter2
Pages19-49
Number of pages31
ISBN (Print)9780128164228
DOIs
Publication statusPublished - 2020

Cite this